The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

PN6047 was also completely devoid of adverse events typically associated with conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or untoward effects following withdrawal symptoms. This validates the unique preclinical profile of PN6047, which shows that it acts very selectively on the delta opioid receptor, distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.

With the Phase I trial's final report at hand and after fruitful discussions with clinical Key Opinion Leaders on designing the Phase IIa Proof of Concept study, PharmNovo is well-prepared to move PN6047 into the next stages of clinical testing.

‍

• Dagens Industri
• Pressrelease